Intravitreal injection: balancing the risks

Chong, Victor; Adewoyin, T.

doi:10.1038/sj.eye.6702699

Cited by 6 publications

(3 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This may be more significant when there is a breakdown in the blood retinal barrier which accompanies some ocular diseases 21, 22. A recent study has also shown that the effect of the monoclonal antibody dosage even in small amounts is often not linear, and thus, a small dose might have significant effects, which could be cumulative with repeated dosing 23 …”

Section: Discussionmentioning

confidence: 99%

Intravitreal bevacizumab versus ranibizumab: Effects on the vessels of the fellow non-treated eye

Peyman¹,

Peyman

Lansingh³

et al. 2019

Journal of Current Ophthalmology

View full text Add to dashboard Cite

Purpose To evaluate the effects of anti-vascular endothelial growth factors (anti-VEGF) on the vessels of the non-treated eyes following intravitreal injections. Methods In this prospective, non-randomized trial, a total of 38 patients were recruited. 21 patients received ranibizumab, and 17 patients received bevacizumab. Fundus photography was carried out at baseline immediately before injection and at 3 days, 7 days, and one month after the injections. Using image analysis software, measurements were summarized as the central retinal artery equivalent (CRAE) and central retinal vein equivalent. Results In non-treated eyes, CRAE decreased significantly from 153.23 ± 15.20 μm before injection to 148.77 ± 17.21 μm 3 days after intravitreal bevacizumab ( P = 0.004). There was no significant difference in CRAE, between the pre-injection baseline, one week, and one month after intravitreal bevacizumab injection in non-treated eyes ( P > 0.05). No significant difference was noted in CRAE in the non-treated eyes of the ranibizumab group at any post-injection visit ( P = 0.1). Conclusion A significant transient narrowing effect of bevacizumab on retinal arterioles in the fellow non-treated eyes on the third day after intravitreal injection may show that plasma concentrations of these drugs are sufficient to spread the effect to the other eye.

show abstract

Section: Discussionmentioning

confidence: 99%

Intravitreal bevacizumab versus ranibizumab: Effects on the vessels of the fellow non-treated eye

Peyman¹,

Peyman

Lansingh³

et al. 2019

Journal of Current Ophthalmology

View full text Add to dashboard Cite

show abstract

“…The simplest approach would be intravitreal injection that allows free diffusion within the vitreous body and retina. Intravitreal injection gained its place in management of eye diseases; however, few data on long-term risk evaluation are yet available (Chong and Adewoyin 2007). Acute effects of intravitreal triamcinolone include increased intraocular pressure, glaucoma and sometimes endophthalmitis (Sampat and Garg 2010).…”

Section: Approaches Of Aav Deliverymentioning

confidence: 99%

Adeno-associated virus (AAV) based gene therapy for eye diseases

Wang

Liu

Song³

et al. 2011

Cell Tissue Bank

View full text Add to dashboard Cite

Gene therapy emerged as important approach in treatment for many inborn disorders caused by genetic defects, as well as other diseases. This manuscript focused on Adeno-associated virus (AAV) based gene therapy to eye diseases. The paper firstly introduced the AAV vectors and the techniques of eye delivery, then summarized some tested genes that were used in past treatment to retinal degeneration disorders. Finally the paper discussed the updated optogenetics and its roles in AAV based gene therapy for eye diseases.

show abstract

“…1,21 However, drug administration through this route is invasive and carries the risk of significant complications, giving a relatively high cost-to-benefit ratio. 22 Oligoarginine CPPs of varying lengths have previously been used to aid drug delivery. For example, protein-peptide complexes have been formed from intermolecular interactions between oligoarginine and insulin proteins.…”

mentioning

confidence: 99%

Topical Delivery of Anti-VEGF Drugs to the Ocular Posterior Segment Using Cell-Penetrating Peptides

Cogan

Hill

Lynch

et al. 2017

Invest. Ophthalmol. Vis. Sci.

View full text Add to dashboard Cite

CPPs are nontoxic to ocular cells and can be used to deliver therapeutically relevant doses of ranibizumab and bevacizumab by eye drop to the posterior segment of mouse, rat, and pig eyes. The CPP + anti-VEGF drug complexes were cleared from the retina within 24 hours, suggesting a daily eye drop dosing regimen. Daily, topically delivered anti-VEGF with CPP was as efficacious as a single ivit injection of anti-VEGF in reducing areas of CNV in vivo.

show abstract

Intravitreal injection: balancing the risks

Cited by 6 publications

References 28 publications

Intravitreal bevacizumab versus ranibizumab: Effects on the vessels of the fellow non-treated eye

Intravitreal bevacizumab versus ranibizumab: Effects on the vessels of the fellow non-treated eye

Adeno-associated virus (AAV) based gene therapy for eye diseases

Topical Delivery of Anti-VEGF Drugs to the Ocular Posterior Segment Using Cell-Penetrating Peptides

Contact Info

Product

Resources

About